https://www.selleckchem.com/products/plx8394.html
Tofacitinib (TOFA) is the first Janus kinase (JAK) inhibitor approved for Psoriatic Arthritis (PsA). It has shown efficacy in patients refractory to anti-TNFα in Randomized Clinical Trials (RCT). Our aim was to assess efficacy and safety of TOFA in clinical practice. Observational, open-label multicenter study of PsA patients treated with TOFA due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, sparing corticosteroid-dose effect, retention rate and safety. Comparative study of clinical features be
Like
Comment
Share
